2 results
Approved WMOCompleted
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
Approved WMOCompleted
The SyncAV Post-Market Trial will evaluate changes in LV end-systolic volume (LVESV) between baseline (before CRT implant) and 12 months (post-randomization) in patients with CRT devices programmed with SyncAV compared to patients with CRT devices…